ITI Pharma and Healthcare Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 9 Nov 2026
- ₹18.71+2.83%1 day
- Return since launch
- 12.7%
- 52-week range
- ₹14.50 — ₹18.45
- AUM
- ₹266 Cr
ITI Pharma and Healthcare Fund is a Sectoral-Pharma equity fund from ITI Mutual Fund with ₹266 Cr under management, launched in 2021. Over three years it has returned 13.3% a year, against 21.2% for its category. The expense ratio is 2.59% and the SEBI riskometer reading is Very High.
Performance
ITI Pharma and Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +14.8% against +19.4% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 26.9% | +6.1 pts | 20.8% | 29.1% |
| 2Y | 14.1% | −5.0 pts | 19.1% | 17.6% |
| 3Y | 13.3% | −8.0 pts | 21.2% | 16.0% |
| 5Y | 16.5% | +1.1 pts | 15.4% | 18.5% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.3% | −0.1 pts | 8.4% | 8.5% |
| 3M | 2.8% | −0.9 pts | 3.7% | 3.7% |
| 6M | 11.8% | −2.2 pts | 14.0% | 13.6% |
| 1Y | 14.8% | −5.9 pts | 20.8% | 19.4% |
| 2Y | 5.7% | −5.1 pts | 10.8% | 9.5% |
| 3Y | 18.5% | −2.7 pts | 21.2% | 20.0% |
| 5Y | 13.3% | −2.1 pts | 15.4% | 14.6% |
Since launch (18 Oct 2021): 12.7%
Calendar-year returns
Category average-8.7%
31.6%
40.9%
-10.0%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -10.0% | −7.9 pts | -2.0% |
| 2024 | 40.9% | 0.0 pts | 40.9% |
| 2023 | 31.6% | −4.6 pts | 36.2% |
| 2022 | -8.7% | −0.4 pts | -8.3% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.57%
Expense ratio as on 6 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.10%
- Brokerage
- 0.06%
- Transaction charges
- 0.00%
- Statutory levies
- 0.41%
- Exit load
- Exit load of 0.50%, if redeemed within 3 months.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- NIFTY Healthcare TRI.
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -4.15 | 1.49 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 1.00 | 0.94 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.76 | 1.10 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.11 | 1.81 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 16.48 | 15.62 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
ITI Pharma and Healthcare Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity99.3%
- Other0.7%
Market cap split
- Large36.1%
- Mid40.7%
- Small23.1%
- P/E
- 47.14
- P/B
- 5.87
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 11.96% | ₹31.82 Cr | +13.34% | +11.80% | +10.62% |
| Divi's Laboratories Ltd. | Healthcare | 9.51% | ₹25.30 Cr | +6.79% | +8.77% | +7.79% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.45% | ₹14.49 Cr | +6.22% | +6.60% | +5.81% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 4.78% | ₹12.72 Cr | +5.44% | +1.87% | +2.45% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.78% | ₹12.71 Cr | +4.56% | +5.28% | +4.59% |
| Max Healthcare Institute Ltd. | Healthcare | 4.49% | ₹11.93 Cr | +5.41% | +5.50% | +5.70% |
| Cipla Ltd. | Healthcare | 4.19% | ₹11.14 Cr | +4.60% | +1.67% | +2.21% |
| Laurus Labs Ltd. | Healthcare | 4.02% | ₹10.70 Cr | +4.40% | +3.65% | +1.31% |
| Aurobindo Pharma Ltd. | Healthcare | 4.01% | ₹10.68 Cr | +4.10% | +4.99% | +3.62% |
| Mankind Pharma Ltd. | Healthcare | 3.78% | ₹10.05 Cr | +2.84% | +1.85% | +2.93% |
| Cohance Lifesciences Ltd. | Healthcare | 3.14% | ₹8.34 Cr | +2.89% | +2.09% | +5.06% |
| Alkem Laboratories Ltd. | Healthcare | 3.09% | ₹8.22 Cr | +2.75% | +3.12% | +2.98% |
| Neuland Laboratories Ltd. | Healthcare | 3.07% | ₹8.16 Cr | +3.09% | +2.66% | +2.57% |
| Global Health Ltd. | Healthcare | 2.85% | ₹7.59 Cr | +2.01% | — | — |
| Fortis Healthcare Ltd. | Healthcare | 2.77% | ₹7.37 Cr | +2.94% | +2.91% | +4.13% |
| Abbott India Ltd. | Healthcare | 2.14% | ₹5.70 Cr | +1.82% | +2.32% | +2.19% |
| Lupin Ltd. | Healthcare | 2.04% | ₹5.43 Cr | +3.30% | +4.20% | +3.04% |
| Ipca Laboratories Ltd. | Healthcare | 1.94% | ₹5.17 Cr | +1.52% | +1.70% | +1.33% |
| Sai Life Sciences Ltd. | Healthcare | 1.87% | ₹4.97 Cr | +1.30% | +1.82% | +1.73% |
| Shilpa Medicare Ltd. | Healthcare | 1.61% | ₹4.29 Cr | +1.18% | +0.82% | +0.82% |
| Aster DM Quality Care Ltd. | Healthcare | 1.59% | ₹4.24 Cr | +1.54% | +2.32% | +3.45% |
| Poly Medicure Ltd. | Healthcare | 1.48% | ₹3.94 Cr | +1.28% | +0.68% | +0.93% |
| Healthcare Global Enterprises Ltd. | Healthcare | 1.47% | ₹3.90 Cr | +1.09% | +1.24% | +1.79% |
| Piramal Pharma Ltd. | Healthcare | 1.27% | ₹3.38 Cr | +1.14% | +1.10% | +0.51% |
| Anthem Biosciences Ltd. | Healthcare | 1.25% | ₹3.32 Cr | — | — | — |
| Shaily Engineering Plastics Ltd. | Materials | 1.22% | ₹3.24 Cr | +1.22% | +1.11% | — |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 1.13% | ₹3.00 Cr | +1.12% | +2.15% | +1.17% |
| Gland Pharma Ltd. | Healthcare | 1.03% | ₹2.74 Cr | — | — | — |
| Rainbow Children's Medicare Ltd. | Healthcare | 1.00% | ₹2.65 Cr | +1.02% | +1.11% | +1.21% |
| Supriya Lifescience Ltd. | Healthcare | 1.00% | ₹2.66 Cr | +1.03% | +0.67% | +1.07% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 0.96% | ₹2.55 Cr | +0.90% | +1.00% | +0.93% |
| Linde India Ltd. | Chemicals | 0.92% | ₹2.45 Cr | +1.25% | +1.39% | +0.86% |
| Biocon Ltd. | Healthcare | 0.81% | ₹2.17 Cr | +0.97% | +1.29% | +0.67% |
| Zydus Lifesciences Ltd. | Healthcare | 0.73% | ₹1.95 Cr | +0.74% | +0.69% | +0.63% |
| Metropolis Healthcare Ltd. | Healthcare | 0.71% | ₹1.89 Cr | — | — | — |
| Others | Others | 0.69% | ₹1.88 Cr | +3.22% | +0.82% | +1.47% |
| Caplin Point Laboratories Ltd. | Healthcare | 0.68% | ₹1.82 Cr | +0.59% | +0.74% | +0.86% |
| Syngene International Ltd. | Healthcare | 0.57% | ₹1.51 Cr | +0.39% | +0.41% | +0.47% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Thyrocare Technologies Ltd. | 1.05% | 0.00% | -1.05% |
| Gland Pharma Ltd. | 0.00% | 1.03% | +1.03% |
| Sun Pharmaceutical Industries Ltd. | 12.58% | 11.96% | -0.62% |
| Dr. Reddy's Laboratories Ltd. | 4.31% | 4.78% | +0.47% |
| Mankind Pharma Ltd. | 3.31% | 3.78% | +0.47% |
| Lupin Ltd. | 2.43% | 2.04% | -0.39% |
| Max Healthcare Institute Ltd. | 4.84% | 4.49% | -0.35% |
| Sai Life Sciences Ltd. | 1.59% | 1.87% | +0.28% |
| Divi's Laboratories Ltd. | 9.23% | 9.51% | +0.28% |
| Apollo Hospitals Enterprise Ltd. | 5.72% | 5.45% | -0.27% |
| Supriya Lifescience Ltd. | 0.81% | 1.00% | +0.19% |
| Abbott India Ltd. | 1.97% | 2.14% | +0.17% |
| Alkem Laboratories Ltd. | 2.92% | 3.09% | +0.17% |
| Global Health Ltd. | 2.98% | 2.85% | -0.13% |
| Aster DM Quality Care Ltd. | 1.47% | 1.59% | +0.12% |
| Neuland Laboratories Ltd. | 3.18% | 3.07% | -0.11% |
| Healthcare Global Enterprises Ltd. | 1.55% | 1.47% | -0.08% |
| Caplin Point Laboratories Ltd. | 0.61% | 0.68% | +0.07% |
| Linde India Ltd. | 0.99% | 0.92% | -0.07% |
| Rainbow Children's Medicare Ltd. | 0.93% | 1.00% | +0.07% |
| Glaxosmithkline Pharmaceuticals Ltd. | 1.02% | 0.96% | -0.06% |
| Biocon Ltd. | 0.87% | 0.81% | -0.06% |
| Piramal Pharma Ltd. | 1.32% | 1.27% | -0.05% |
| Fortis Healthcare Ltd. | 2.82% | 2.77% | -0.05% |
| Cohance Lifesciences Ltd. | 3.10% | 3.14% | +0.04% |
| Others | 0.73% | 0.69% | -0.04% |
| Aurobindo Pharma Ltd. | 3.97% | 4.01% | +0.04% |
| Torrent Pharmaceuticals Ltd. | 4.75% | 4.78% | +0.03% |
| Metropolis Healthcare Ltd. | 0.74% | 0.71% | -0.03% |
| Shaily Engineering Plastics Ltd. | 1.25% | 1.22% | -0.03% |
| Syngene International Ltd. | 0.60% | 0.57% | -0.03% |
| Cipla Ltd. | 4.22% | 4.19% | -0.03% |
| Glenmark Pharmaceuticals Ltd. | 1.15% | 1.13% | -0.02% |
| Ipca Laboratories Ltd. | 1.92% | 1.94% | +0.02% |
| Poly Medicure Ltd. | 1.50% | 1.48% | -0.02% |
| Shilpa Medicare Ltd. | 1.59% | 1.61% | +0.02% |
| Zydus Lifesciences Ltd. | 0.71% | 0.73% | +0.02% |
| Anthem Biosciences Ltd. | 1.25% | 1.25% | 0.00% |
| Laurus Labs Ltd. | 4.02% | 4.02% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,934 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund managers
- Animesh SinghPost Graduate Diploma in Management, Bachelor of Honours -(Economics) CFA - USA Certification.Prior to joining the ITI AMC, he was associated with Julius Baer wealth Advisor, Centrum Wealth, Nippon Life India Asset Management Ltd, Reliance Portfolio Management Services, KSBL and SSKI Securities.
- Nilay DalalMr. Nilay holds a degree in B.E (Computer) from D.J Sanghvi College of Engg & masterâs in management studies in KJ Somaiya Institute of Management Studies & Research.Prior to joining ITI Mutual Fund, he has with Axis Asset Management Company, SBI Life Insurance Company Ltd & MAQ Software Pvt Ltd.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months11.85% absolute | ₹60,000 | ₹67,110 | 11.85% | |
| 1 year14.85% annualised | ₹1,20,000 | ₹1,30,104 | 8.42% | |
| 3 years18.50% annualised | ₹3,60,000 | ₹4,83,830 | 34.40% | |
| 5 years13.34% annualised | ₹6,00,000 | ₹8,56,093 | 42.68% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of ITI Pharma and Healthcare Fund?
The NAV of ITI Pharma and Healthcare Fund is ₹18.71 as on 9 Nov 2026.
What is the expense ratio of ITI Pharma and Healthcare Fund?
The expense ratio of ITI Pharma and Healthcare Fund is 2.59% per year.
What is the minimum SIP amount for ITI Pharma and Healthcare Fund?
You can start a SIP in ITI Pharma and Healthcare Fund with ₹3,000 a month.
What returns has ITI Pharma and Healthcare Fund given?
ITI Pharma and Healthcare Fund has returned 26.9% over 1 year, 13.3% over 3 years and 16.5% over 5 years (annualised).
Is there a lock-in or exit load on ITI Pharma and Healthcare Fund?
Lock-in: None. Exit load: Exit load of 0.50%, if redeemed within 3 months..
How risky is ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is managed by ITI Mutual Fund, which runs 20 schemes with ₹12,469 Cr under management.